As of 2025-07-06, the Relative Valuation of Neovacs SA (ALNEV.PA) is (245.54) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.00 EUR, the upside of Neovacs SA based on Relative Valuation is -11160893.1%.
The range of the Relative Valuation is (279.90) - (186.93) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 9.0x - 15.0x | 11.3x |
| Forward P/E multiples | 22.4x - 29.6x | 28.0x |
| Fair Price | (279.90) - (186.93) | (245.54) |
| Upside | -12722836.2% - -8497070.2% | -11160893.1% |
| Date | P/E |
| 2025-07-03 | -0.00 |
| 2025-07-02 | -0.00 |
| 2025-07-01 | -0.00 |
| 2025-06-30 | -0.00 |
| 2025-06-27 | -0.00 |
| 2025-06-26 | -0.00 |
| 2025-06-25 | -0.00 |
| 2025-06-24 | -0.00 |
| 2025-06-23 | -0.00 |
| 2025-06-20 | -0.00 |
| 2025-06-19 | -0.00 |
| 2025-06-18 | -0.00 |
| 2025-06-17 | -0.00 |
| 2025-06-16 | -0.00 |
| 2025-06-13 | -0.00 |
| 2025-06-12 | -0.00 |
| 2025-06-11 | -0.00 |
| 2025-06-10 | -0.00 |
| 2025-06-09 | -0.00 |
| 2025-06-06 | -0.00 |
| 2025-06-05 | -0.00 |
| 2025-06-04 | -0.00 |
| 2025-06-03 | -0.00 |
| 2025-06-02 | -0.00 |
| 2025-05-30 | -0.00 |
| 2025-05-29 | -0.00 |
| 2025-05-28 | -0.00 |
| 2025-05-27 | -0.00 |
| 2025-05-26 | -0.00 |
| 2025-05-23 | -0.00 |
| 2025-05-22 | -0.00 |
| 2025-05-21 | -0.00 |
| 2025-05-20 | -0.00 |
| 2025-05-19 | -0.00 |
| 2025-05-16 | -0.00 |
| 2025-05-15 | -0.00 |
| 2025-05-14 | -0.00 |
| 2025-05-13 | -0.00 |
| 2025-05-12 | -0.00 |
| 2025-05-09 | -0.00 |
| 2025-05-08 | -0.00 |
| 2025-05-07 | -0.00 |
| 2025-05-06 | -0.00 |
| 2025-05-05 | -0.00 |
| 2025-05-02 | -0.00 |
| 2025-04-30 | -0.00 |
| 2025-04-29 | -0.00 |
| 2025-04-28 | -0.00 |
| 2025-04-25 | -0.00 |
| 2025-04-24 | -0.00 |